Beneficial effects of tumor necrosis factor-α inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis

American Journal of Gastroenterology

Volumn 99, Issue 10, 2004, Pages 1946-1952

  Satapathy, Sanjay K ^a   Garg, Sanjay ^a   Chauhan, Ranjeet ^a   Sakhuja, Puja ^a   Malhotra, Veena ^a   Sharma, Barjesh C ^a   Sarin, Shiv K ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; PENTOXIFYLLINE; PROTON PUMP INHIBITOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIVER BIOPSY; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; OPEN STUDY; OUTCOMES RESEARCH; PARAMETER; PATHOPHYSIOLOGY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SYMPTOM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; FATTY LIVER; HUMANS; MALE; MIDDLE AGED; PENTOXIFYLLINE; PILOT PROJECTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 7044269614     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.40220.x     Document Type: Article

References (40)

1. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
2. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
3. Pares A, Caballeria J, Bruguera M, et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986;2:33-42.
4. Galambos JT. Natural history of alcoholic hepatitis. Histological changes. Gastroenterology 1972;63:1026-35.
5. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-11.
6. Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001;34:1158-63.
7. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997;94:2557-62.
8. McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: Down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses. 1999;52:465-77.
9. Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 1993;187:447-63.
10. Rieckmann P, Weber F, Gunther A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996;64:193-200.
11. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-48.
12. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
13. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998;6(suppl II):51S-209S.
14. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: Is biopsy necessary? Eur J Gastroenterol Hepatol 2003;15:539-43.
15. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in patients with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
16. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-97.
17. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): A disease of emerging identity and importance. J Hepatol 1998;29:495-501.
18. Scheen AJ, Luyckx FH. Nonalcoholic steatohepatitis and insulin resistance: Interface between gastroenterologists and endocrinologists. Acta Clin Belg 2003;58:81-91.
19. Saglam K, Kilic R, Yilmaz MI, et al. Insulin resistance in patients with steatohepatitis. Hepatogastroenterology 2003;50:456-9.
20. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19
21. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271:665-8.
22. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-4.
23. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
24. Lee RG. Nonalcoholic steatohepatitis: A study of 49 patients. Hum Pathol 1989;20:594-8.
25. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 1970;282:829-34.
26. Rozental P, Biava C, Spencer H, et al. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967;12:198-208.
27. Lavine JE. Treatment of obesity-induced steatohepatitis with vitamine E. Gastroenterology 1998;114:A1284.
28. Fu CS, Esrason K, Alshak NS, et al. Dietary lecithin, anti oxidant and vitamin B complex (LAB) decrease hepatic steatosis on patients with nonalcoholic staetohepatitis. Gastroenterology 1998;114:A1284.
29. Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study. Am J Gastroenterol 2001;96:2711-7.
30. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology 1996;23:1464-7.
31. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999;31:384.
32. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-25.
33. Sanyal AJ. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.
34. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001;92(6 suppl):1684-8.
35. Moss RB, Mercandetti A, Vojdani A. TNF-alpha and chronic fatigue syndrome. J Clin Immunol 1999;19:314-6.
36. Dreisbach AW, Hendrickson T, Beezhold D, et al. Elevated levels of tumor necrosis factor alpha in postdialysis fatigue. Int J Artif Organs 1998;21:83-6.
37. Cicoira M, Bolger AP, Doehner W, et al. High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine 2001;15:80-6.
38. Steensma DP, Mesa RA, Li CY, et al. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: Results of a pilot study. Blood 2002;99:2252-4.
39. Tuckey JA, Parry BR, McCall JL. Pentoxifylline and well-being in cancer. Lancet 1993;342:617.
40. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97.